No Data
No Data
No Data
No Data
No Data
Polycythemia Pipeline Insight 2024, Featuring Protagonist Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, Imago BioSciences, Incyte, Italfarmaco, Lynk and Promedior
Yahoo FinanceApr 18 03:53 ET
Form 144 | Ionis Pharmaceuticals(IONS.US) Officer Proposes to Sell 168.25K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 16, $Ionis Pharmaceuticals(IONS.US)$ Officer Baroldi Joseph intends to sell 4,006 shares of its common stock on Apr 16, with a total market value of approximately $168.25K.
moomoo NewsApr 16 21:02 ET
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Right But Growth Is Lacking
You may think that with a price-to-sales (or "P/S") ratio of 7.7x Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a stock worth checking out, seeing as almost half of all the Biotechs companies in the Un
Simply Wall StApr 15 11:23 ET
Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts
Seeking AlphaApr 10 12:03 ET
Express News | Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform
Moomoo 24/7Apr 10 04:32 ET
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Seeking AlphaApr 9 10:03 ET
No Data
No Data